EDAP Technomed, Inc.
Developer and vendor of a clinician‑controlled robotic platform for targeted, non‑invasive tissue ablation using high‑intensity focused ultrasound (HIFU). The platform integrates multi‑axis robotic probe positioning, a dynamic focusing therapy transducer with real‑time transrectal ultrasound imaging, multi‑modal image‑fusion planning software with DICOM interoperability and AI‑assisted registration, automated safety subsystems including rectal cooling management and motion detection, and clinical program support including training and remote proctoring. The organisation supports clinical evidence generation and centre partnerships to aid program adoption and has regulatory clearance for additional indications including deep posterior endometriosis in Europe.
Industries
N/A
Nr. of Employees
small (1-50)
EDAP Technomed, Inc.
5321 Industrial Oaks Blvd, Suite 110, Austin, TX 78735, United States
Products
Robotic focal HIFU treatment system
Integrated clinician‑controlled platform combining robotic probe positioning, a dynamic focusing therapy transducer with integrated ultrasound imaging, multi‑modal image‑fusion planning software, and automated safety subsystems for targeted tissue ablation.
Robotic focal HIFU treatment system
Integrated clinician‑controlled platform combining robotic probe positioning, a dynamic focusing therapy transducer with integrated ultrasound imaging, multi‑modal image‑fusion planning software, and automated safety subsystems for targeted tissue ablation.
Services
Onboarding, procedural training, educational content, guided workflows, integrated video resources, webinars and remote proctoring to support hospitals and urology practices deploying focal therapy programs.
Provision and collation of peer‑reviewed studies, support for multi‑center trials and dissemination of clinical outcome data to clinician investigators and health systems.
Onboarding, procedural training, educational content, guided workflows, integrated video resources, webinars and remote proctoring to support hospitals and urology practices deploying focal therapy programs.
Provision and collation of peer‑reviewed studies, support for multi‑center trials and dissemination of clinical outcome data to clinician investigators and health systems.
Expertise Areas
- Focal HIFU therapy for prostate disease
- Robotic image‑guided probe positioning
- Multi‑modal image fusion (MRI, PSMA‑PET, biopsy mapping)
- Image registration and AI‑assisted image processing
Key Technologies
- High‑intensity focused ultrasound (HIFU)
- Phased‑array dynamic focusing transducers
- Robotic multi‑axis positioning (5 DOF)
- Real‑time transrectal ultrasound imaging and 3D reconstruction
News & Updates
Company participation in a public health event organised by the French urology association to raise awareness for male health and screening.
Virtual event covering diagnosis and non‑surgical focal HIFU treatment with regional urologists.
Reference to a large prospective, multi‑center comparative study evaluating focal HIFU versus radical prostatectomy with reported outcomes on safety and function.
Local news coverage describing adoption of robotic HIFU as a minimally invasive treatment option and a centre offering the procedure.
Regulatory certification (CE mark) granted in March 2025 for an additional indication involving posterior deep endometriosis infiltrating the rectum and surrounding structures.
Site‑reported adoption metrics citing more than 50,000 treatments performed worldwide, 300+ treatment centres and 100+ peer‑reviewed publications.
Company participation in a public health event organised by the French urology association to raise awareness for male health and screening.
Virtual event covering diagnosis and non‑surgical focal HIFU treatment with regional urologists.
Reference to a large prospective, multi‑center comparative study evaluating focal HIFU versus radical prostatectomy with reported outcomes on safety and function.
Local news coverage describing adoption of robotic HIFU as a minimally invasive treatment option and a centre offering the procedure.
Regulatory certification (CE mark) granted in March 2025 for an additional indication involving posterior deep endometriosis infiltrating the rectum and surrounding structures.
Site‑reported adoption metrics citing more than 50,000 treatments performed worldwide, 300+ treatment centres and 100+ peer‑reviewed publications.